

LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material	Moxifloxacin Ophthalmic Solution USP, 0.5%
Manufacturer	Lupin Limited Pithampur (M. P.), 454 775 India.
Distributor	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Note	This product is Non-Hazardous and is approved by the FDA. It is an aqueous solution and is not considered to constitute a Hazard.
Health	None
Environment	No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients	CAS
Moxifloxacin Hydrochloride USP	186826-86-8

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion	Flush the mouth with water. Obtain medical attention.
Inhalation	Move individual to fresh air. Obtain medical attention.
Skin Contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Eye Contact

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

NOTES TO HEALTH PROFESSIONALS**Medical Treatment**

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

Section 5: Fire-Fighting Measures**Section 5, Fire-fighting measures****Fire and Explosion Hazards**

Assume that this product is capable of sustaining combustion.

Extinguishing Media

Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures

For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products

Hazardous combustion or decomposition products are expected when the product is exposed to fire.

Section 6: Accidental Release Measures**Section 6, Accidental release measures****Personal Precautions**

Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions

For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods

Collect and place it in a suitable, properly labeled container for recovery or disposal.

Section 7: Handling and Storage**Section 7, Handling and storage****Handling**

No special measures required.

Storage

Storage: Store at 2°C to 25°C (36°F to 77°F).

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form

HOW SUPPLIED

Moxifloxacin ophthalmic solution USP, 0.5% is supplied as a sterile ophthalmic solution in a sterile 5 mL natural low density polyethylene bottle fitted with a natural low density polyethylene nozzle and sealed with a tan coloured high density polyethylene cap as follows:

3 mL in a 5 mL bottle (NDC 68180-421-01)

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed.

Moxifloxacin was not mutagenic in four bacterial strains used in the Ames *Salmonella* reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity *in vivo* in a micronucleus test or a dominant lethal test in mice.

Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 25,000 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to

determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.